TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Populationbased Screening for Urogenital Chlamydia Trachomatis Infections by Use of Home-Obtained and Mailed Samples: A Randomized Study
Brief Summary: 30,000 individuals living in Aarhus County, Denmark by Oct 1997 were randomized into two groups. The intervention group received an invitation to be tested for urogenital Chlamydia trachomatis by use of home-obtained and mailed sample (9,000 individuals). The control group received no intervention (21,000 individuals). Outcome measures: Number of tested individuals, number of detected infections, number of women developing PID, ectopic pregnancy or infertility, number of women giving birth to a child, number of women receiving IVF treatment and number of men developing epididymitis.

The hypothesis was that more individuals would be tested and treated for infections and that number of long term fertility complications would decline in the intervention group compared to control group.


Options:
A: Arm Label: Active azithromycin+placebo doxycycline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Active doxycycline+placebo azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Doxycycline | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Active azithromycin+placebo doxycycline | Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): Active doxycycline+placebo azithromycin
B: Intervention Type: BEHAVIORAL; Name: home testing kit; Assigned to Arm(s): N/A
C: Arm Label: Deferred screening control group; Type: OTHER; Interventions: Procedure: Screening for chlamydia using self-taken vaginal swabs | Intervention Type: PROCEDURE; Name: Screening for chlamydia using self-taken vaginal swabs; Assigned to Arm(s): Deferred screening control group
D: Arm Label: 1 Screening; Type: EXPERIMENTAL; Interventions: Behavioral: Screening for urogenital Chlamydia trachomatis | Arm Label: 2 Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Screening for urogenital Chlamydia trachomatis; Assigned to Arm(s): 1 Screening

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Populationbased Screening for Urogenital Chlamydia Trachomatis Infections by Use of Home-Obtained and Mailed Samples: A Randomized Study
Brief Summary: 30,000 individuals living in Aarhus County, Denmark by Oct 1997 were randomized into two groups. The intervention group received an invitation to be tested for urogenital Chlamydia trachomatis by use of home-obtained and mailed sample (9,000 individuals). The control group received no intervention (21,000 individuals). Outcome measures: Number of tested individuals, number of detected infections, number of women developing PID, ectopic pregnancy or infertility, number of women giving birth to a child, number of women receiving IVF treatment and number of men developing epididymitis.

The hypothesis was that more individuals would be tested and treated for infections and that number of long term fertility complications would decline in the intervention group compared to control group.


Options:
A: Intervention Type: PROCEDURE; Name: Self-collected vaginal swab for chlamydia testing; Assigned to Arm(s): N/A
B: Intervention Type: PROCEDURE; Name: Home sampling (urine test) for uro-genital C.trachomatis.; Assigned to Arm(s): N/A
C: Arm Label: 1 Screening; Type: EXPERIMENTAL; Interventions: Behavioral: Screening for urogenital Chlamydia trachomatis | Arm Label: 2 Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Screening for urogenital Chlamydia trachomatis; Assigned to Arm(s): 1 Screening
D: Intervention Type: BEHAVIORAL; Name: home testing kit; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Tolerability of Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support in Patients Undergoing In-Vitro Fertilization (IVF)
Brief Summary: Prospective, open, randomised, parallel, multicentre, two arm trial comparing a new form of luteal support (S.C.) to an approved comparator (vaginal gel).


Options:
A: Arm Label: Progesterone 5 Weeks; Type: ACTIVE_COMPARATOR; Interventions: Other: Cease progsterone at 5 | Arm Label: Control Group : P4 8 weeks; Type: OTHER; Interventions: Other: control group: progesterone 8 | Intervention Type: OTHER; Name: Cease progsterone at 5; Assigned to Arm(s): Progesterone 5 Weeks | Intervention Type: OTHER; Name: control group: progesterone 8; Assigned to Arm(s): Control Group : P4 8 weeks
B: Arm Label: Progesterone SC; Type: EXPERIMENTAL; Interventions: Drug: Progesterone | Arm Label: Progesterone Vaginal gel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Progesterone SC | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Progesterone Vaginal gel
C: Arm Label: Oral dydrogesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral dydrogesterone | Arm Label: Crinone 8% vaginal gel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Crinone 8% gel | Intervention Type: DRUG; Name: Oral dydrogesterone; Assigned to Arm(s): Oral dydrogesterone | Intervention Type: DRUG; Name: Crinone 8% gel; Assigned to Arm(s): Crinone 8% vaginal gel
D: Arm Label: Subcutaneous progesterone; Type: EXPERIMENTAL; Interventions: Drug: Subcutaneous progesterone | Arm Label: Vaginal Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vaginal progesterone | Intervention Type: DRUG; Name: Subcutaneous progesterone; Assigned to Arm(s): Subcutaneous progesterone | Intervention Type: DRUG; Name: Vaginal progesterone; Assigned to Arm(s): Vaginal Progesterone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long-term Varenicline Treatment for Smoking Cessation
Brief Summary: This is a clinical study of the efficacy and safety of up to 52 weeks of varenicline therapy in conjunction with individual counseling for smoking cessation. Adult volunteers in generally good health, smoking 5 or more cigarettes per day, will receive 13 weeks of open-label varenicline therapy. At 12 weeks after their target quit date, they will be assigned in a random, double-blind manner to either 40 additional weeks of varenicline or placebo. It is hypothesized that biochemically-confirmed abstinence rates will be higher for the varenicline group at 52 weeks. Participants will be followed for an additional 26 weeks post-treatment.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Behavioral group smoking cessation treatment | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Behavioral group smoking cessation treatment, Drug: Placebo | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Behavioral group smoking cessation treatment; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Extended treatment; Type: EXPERIMENTAL; Interventions: Drug: varenicline, Behavioral: Individual smoking cessation counseling | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline, Behavioral: Individual smoking cessation counseling | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Extended treatment, Standard treatment | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Extended treatment, Standard treatment | Intervention Type: BEHAVIORAL; Name: Individual smoking cessation counseling; Assigned to Arm(s): Extended treatment, Standard treatment
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone, Drug: Varenicline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long-term Varenicline Treatment for Smoking Cessation
Brief Summary: This is a clinical study of the efficacy and safety of up to 52 weeks of varenicline therapy in conjunction with individual counseling for smoking cessation. Adult volunteers in generally good health, smoking 5 or more cigarettes per day, will receive 13 weeks of open-label varenicline therapy. At 12 weeks after their target quit date, they will be assigned in a random, double-blind manner to either 40 additional weeks of varenicline or placebo. It is hypothesized that biochemically-confirmed abstinence rates will be higher for the varenicline group at 52 weeks. Participants will be followed for an additional 26 weeks post-treatment.


Options:
A: Arm Label: Extended treatment; Type: EXPERIMENTAL; Interventions: Drug: varenicline, Behavioral: Individual smoking cessation counseling | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline, Behavioral: Individual smoking cessation counseling | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Extended treatment, Standard treatment | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Extended treatment, Standard treatment | Intervention Type: BEHAVIORAL; Name: Individual smoking cessation counseling; Assigned to Arm(s): Extended treatment, Standard treatment
B: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Nicotine Patches only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches | Arm Label: Nicotine Patches with Nicotine Inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, Drug: Nicotine Inhaler | Arm Label: varenicline with bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline, varenicline with bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): varenicline with bupropion | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Nicotine Patches only, Nicotine Patches with Nicotine Inhaler | Intervention Type: DRUG; Name: Nicotine Inhaler; Assigned to Arm(s): Nicotine Patches with Nicotine Inhaler
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pharmacotherapies for Smoking Cessation | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pharmacotherapies for Smoking Cessation | Intervention Type: DRUG; Name: Pharmacotherapies for Smoking Cessation; Assigned to Arm(s): 1, 2
D: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long-term Varenicline Treatment for Smoking Cessation
Brief Summary: This is a clinical study of the efficacy and safety of up to 52 weeks of varenicline therapy in conjunction with individual counseling for smoking cessation. Adult volunteers in generally good health, smoking 5 or more cigarettes per day, will receive 13 weeks of open-label varenicline therapy. At 12 weeks after their target quit date, they will be assigned in a random, double-blind manner to either 40 additional weeks of varenicline or placebo. It is hypothesized that biochemically-confirmed abstinence rates will be higher for the varenicline group at 52 weeks. Participants will be followed for an additional 26 weeks post-treatment.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chantix, Behavioral: Standard Counseling | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Behavioral: Adherence Counseling, Behavioral: Standard Counseling | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Adherence Counseling; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Standard Counseling; Assigned to Arm(s): 1, 2
B: Arm Label: Extended treatment; Type: EXPERIMENTAL; Interventions: Drug: varenicline, Behavioral: Individual smoking cessation counseling | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline, Behavioral: Individual smoking cessation counseling | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Extended treatment, Standard treatment | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Extended treatment, Standard treatment | Intervention Type: BEHAVIORAL; Name: Individual smoking cessation counseling; Assigned to Arm(s): Extended treatment, Standard treatment
C: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pil; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Sugar Pil
D: Arm Label: Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: Smoking Cessation Counseling | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Bupropion, Placebo, Varenicline

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long-term Varenicline Treatment for Smoking Cessation
Brief Summary: This is a clinical study of the efficacy and safety of up to 52 weeks of varenicline therapy in conjunction with individual counseling for smoking cessation. Adult volunteers in generally good health, smoking 5 or more cigarettes per day, will receive 13 weeks of open-label varenicline therapy. At 12 weeks after their target quit date, they will be assigned in a random, double-blind manner to either 40 additional weeks of varenicline or placebo. It is hypothesized that biochemically-confirmed abstinence rates will be higher for the varenicline group at 52 weeks. Participants will be followed for an additional 26 weeks post-treatment.


Options:
A: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
B: Arm Label: Extended treatment; Type: EXPERIMENTAL; Interventions: Drug: varenicline, Behavioral: Individual smoking cessation counseling | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline, Behavioral: Individual smoking cessation counseling | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Extended treatment, Standard treatment | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Extended treatment, Standard treatment | Intervention Type: BEHAVIORAL; Name: Individual smoking cessation counseling; Assigned to Arm(s): Extended treatment, Standard treatment
C: Arm Label: Varenicline treatment as usual (TAU); Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline directly observed therapy; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline directly observed therapy, Varenicline treatment as usual (TAU)
D: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Internet-delivered Cognitive Behavioural Therapy for Health Anxiety - a Randomized Controlled Trial
Brief Summary: Hypochondriasis (health anxiety) is common, has many negative consequences for the afflicted individual and is associated with high societal costs. Cognitive Behavioural Therapy (CBT) has proven to be effective when administered in live-sessions. The aim of this study is to investigate whether CBT remains effective when administered via a self-help programme on the Internet.


Options:
A: Arm Label: Tailored Internet-delivered CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored Internet-administrated CBT-Treatment | Arm Label: Waitlist; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Waitlist | Intervention Type: BEHAVIORAL; Name: Tailored Internet-administrated CBT-Treatment; Assigned to Arm(s): Tailored Internet-delivered CBT | Intervention Type: BEHAVIORAL; Name: Waitlist; Assigned to Arm(s): Waitlist
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-delivered CBT. | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: On line discussion group | Intervention Type: BEHAVIORAL; Name: Internet-delivered CBT.; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: On line discussion group; Assigned to Arm(s): 2
C: Arm Label: Internet CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based cognitive behavior therapy (CBT). | Arm Label: Group CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Group CBT | Intervention Type: BEHAVIORAL; Name: Internet-based cognitive behavior therapy (CBT).; Assigned to Arm(s): Internet CBT | Intervention Type: BEHAVIORAL; Name: Group CBT; Assigned to Arm(s): Group CBT
D: Arm Label: Internet-based CBT; Type: N/A; Interventions: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Tolerability of Subcutaneous Progesterone (IBSA) Versus Vaginal Progesterone for Luteal Phase Support in Patients Undergoing In Vitro Fertilization (IVF)
Brief Summary: Prospective, open, randomized, parallel, multicenter, two-arm trial to evaluate the efficacy and tolerability of a new progesterone formulation to be used for luteal support in IVF (Progesterone-IBSA) administered subcutaneously at a daily dose of 25 mg versus Progesterone tablets administered intravaginally at 100 mg twice daily for a total dose of 200 mg.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: DR-2011 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Crinone 8% | Intervention Type: DRUG; Name: DR-2011; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Crinone 8%; Assigned to Arm(s): 2
B: Arm Label: Progesterone SC; Type: EXPERIMENTAL; Interventions: Drug: Progesterone | Arm Label: Progesterone Tablets; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Progesterone SC | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Progesterone Tablets
C: Arm Label: Subcutaneous progesterone; Type: EXPERIMENTAL; Interventions: Drug: Subcutaneous progesterone | Arm Label: Vaginal Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vaginal progesterone | Intervention Type: DRUG; Name: Subcutaneous progesterone; Assigned to Arm(s): Subcutaneous progesterone | Intervention Type: DRUG; Name: Vaginal progesterone; Assigned to Arm(s): Vaginal Progesterone
D: Arm Label: Oral dydrogesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral dydrogesterone | Arm Label: Crinone 8% vaginal gel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Crinone 8% gel | Intervention Type: DRUG; Name: Oral dydrogesterone; Assigned to Arm(s): Oral dydrogesterone | Intervention Type: DRUG; Name: Crinone 8% gel; Assigned to Arm(s): Crinone 8% vaginal gel

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Phase III Trial Comparing Induction CT With Docetaxel, Cisplatin and 5-FU (TPF) Followed by Concurrent CT-RT to Concurrent CT Alone, in Nasopharyngeal Cancers Staged as T2b, T3, T4 and/or With Lymph Node Involvement (>N1)
Brief Summary: This is a randomized, multicenter, phase III trial comparing induction chemotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) followed by concurrent chemoradiotherapy to concurrent chemoradiotherapy alone, in nasopharyngeal cancers staged as T2b, T3, T4 and/or with lymph node involvement (≥ N1. The main end point is the event free survival.


Options:
A: Arm Label: Arm I; Type: PLACEBO_COMPARATOR; Interventions: Procedure: conventional surgery, Radiation: radiation therapy | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Biological: cetuximab, Procedure: conventional surgery, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): Arm II | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I, Arm II | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm I, Arm II
B: Intervention Type: DRUG; Name: XRP6976 (Docetaxel/Taxotere); Assigned to Arm(s): N/A
C: Arm Label: RT+CDDP/5-FU; Type: ACTIVE_COMPARATOR; Interventions: Drug: RT+CDDP/5-FU | Arm Label: RT+CETUXIMAB; Type: EXPERIMENTAL; Interventions: Drug: RT+CETUXIMAB | Arm Label: INDUCTION CTx(TPF)+(RT+CDDP/5-FU); Type: ACTIVE_COMPARATOR; Interventions: Drug: INDUCTION CTx(TPF)+(RT+CDDP/5-FU) | Arm Label: INDUCTION CTx(TPF)+(RT+CETUXIMAB); Type: EXPERIMENTAL; Interventions: Drug: INDUCTION CTx(TPF)+(RT+CETUXIMAB) | Intervention Type: DRUG; Name: RT+CDDP/5-FU; Assigned to Arm(s): RT+CDDP/5-FU | Intervention Type: DRUG; Name: RT+CETUXIMAB; Assigned to Arm(s): RT+CETUXIMAB | Intervention Type: DRUG; Name: INDUCTION CTx(TPF)+(RT+CDDP/5-FU); Assigned to Arm(s): INDUCTION CTx(TPF)+(RT+CDDP/5-FU) | Intervention Type: DRUG; Name: INDUCTION CTx(TPF)+(RT+CETUXIMAB); Assigned to Arm(s): INDUCTION CTx(TPF)+(RT+CETUXIMAB)
D: Arm Label: Induction chemotherapy + concurrent chemoradiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy | Arm Label: Concurrent radiochemotherapy alone; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy | Intervention Type: PROCEDURE; Name: Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy; Assigned to Arm(s): Concurrent radiochemotherapy alone, Induction chemotherapy + concurrent chemoradiotherapy

Answer: D